The epidemiology of childhood pneumococcal disease in the united states in the era of conjugate vaccine use

Infectious Disease Clinics of North America

Volumn 19, Issue 3, 2005, Pages 629-645

  Toltzis, Philip ^a   Jacobs, Michael R ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; CHILDHOOD DISEASE; CONJUGATE; COST EFFECTIVENESS ANALYSIS; DRUG USE; DRUG UTILIZATION; HERD IMMUNITY; HUMAN; IMMUNIZATION; MORBIDITY; OTITIS MEDIA; PEDIATRICS; PNEUMONIA; REVIEW; SEROTYPE; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION; TREATMENT FAILURE; UNITED STATES; VACCINATION;

BACTEREMIA; BACTERIAL CAPSULES; CHILD, PRESCHOOL; HUMANS; INFANT; MENINGOCOCCAL VACCINES; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINES, CONJUGATE;

EID: 23644436035     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2005.05.008     Document Type: Review

References (79)

1. Advisory Committee on Immunization Practices Preventing pneumococcal disease among infants and young children MMWR Morb Mort Wkly Rep 2000 49 RR-9:1-35
2. American Academy of Pediatrics Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis Pediatrics 106 2000 362 366
3. CDC Notice to readers: updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose MMWR Morb Mort Wkly Rep 53 2004 177 178
4. CDC National, state, and urban area vaccination coverage among children aged 19-35 months - United States, 2003 MMWR Morb Mort Wkly Rep 53 2004 658 661
5. S. Black, H. Shinefield, and R. Baxter Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente Pediatr Infect Dis J 23 2004 485 489
6. M.L. Joloba, A. Windau, S. Bajaksouzian, P.C. Appelbaum, W.P. Hausdorff, and M.R. Jacobs Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media Clin Infect Dis 33 2001 1489 1494
7. D.R. Feikin, and K.P. Klugman Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines Clin Infect Dis 35 2002 547 555
8. H. Kayhty, H. Ahman, P.R. Ronnberg, R. Tillikainen, and J. Eskola Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children J Infect Dis 172 1995 1273 1278
9. M.B. Rennels, K.M. Edwards, and H.L. Keyserling Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants Pediatrics 101 1998 604 611
10. H. Ahman, H. Kayhty, A. Vuorela, O. Leroy, and J. Eskola Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid Vaccine 17 1999 2726 2732
11. S. Black, H. Shinefield, and B. Fireman Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group Pediatr Infect Dis J 19 2000 187 195
12. H.R. Shinefield, S. Black, and P. Ray Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers Pediatr Infect Dis J 18 1999 757 763
13. H. Ahman, H. Kayhty, H. Lehtonen, O. Leroy, J. Froeschle, and J. Eskola Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory Pediatr Infect Dis J 17 1998 211 216
14. A.M. Stack, R. Malley, C.M. Thompson, L. Kobzik, G.R. Siber, and R.A. Saladino Minimum protective serum concentrations of pneumococcal anti-capsular antibodies in infant rats J Infect Dis 177 1998 986 990
15. R. Dagan, R. Melamed, and M. Muallem Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine J Infect Dis 174 1996 1271 1278
16. R. Dagan, N. Givon-Lavi, and O. Zamir Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers J Infect Dis 185 2002 927 936
17. R. Dagan, M. Muallem, R. Melamed, O. Leroy, and P. Yagupsky Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid Pediatr Infect Dis J 16 1997 1060 1064
18. N. Mbelle, R.E. Huebner, A.D. Wasas, A. Kimura, I. Chang, and K.P. Klugman Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine J Infect Dis 180 1999 1171 1176
19. S.K. Obaro, R.A. Adegbola, W.A. Banya, and B.M. Greenwood Carriage of pneumococci after pneumococcal vaccination Lancet 348 1996 271 272
20. J.A. Finkelstein, S.S. Huang, and J. Daniel Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample Pediatrics 112 2003 862 869
21. S.B. Black, H.R. Shinefield, J. Hansen, L. Elvin, D. Laufer, and F. Malinoski Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine Pediatr Infect Dis J 20 2001 1105 1107
22. B. Flannery, S. Schrag, and N.M. Bennett Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections JAMA 291 2004 2197 2203
23. K.P. Klugman, S.A. Madhi, R.E. Huebner, R. Kohberger, N. Mbelle, and N. Pierce A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection N Engl J Med 349 2003 1341 1348
24. C.G. Whitney, M.M. Farley, and J. Hadler Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine N Engl J Med 348 2003 1737 1746
25. S. Shafinoori, C.C. Ginocchio, A.J. Greenberg, E. Yeoman, M. Cheddie, and L.G. Rubin Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults Pediatr Infect Dis J 24 2005 10 16
26. S.L. Kaplan, E.O. Mason Jr., and E.R. Wald Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine Pediatrics 113 2004 443 449
27. D.S. Stephens, S.M. Zughaier, and C.G. Whitney Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment Lancet 365 2005 855 863
28. K. Hsu, S. Pelton, S. Karumuri, D. Heisey-Grove, and J. Klein Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine Pediatr Infect Dis J 24 2005 17 23
29. P.L. Lin, M.G. Michaels, J. Janosky, M. Ortenzo, E.R. Wald, and E.O. Mason Jr. Incidence of invasive pneumococcal disease in children 3 to 36 months of age at a tertiary care pediatric center 2 years after licensure of the pneumococcal conjugate vaccine Pediatrics 111 2003 896 899
30. N. French, J. Nakiyingi, and L.M. Carpenter 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial Lancet 355 2000 2106 2111
31. S.B. Black, H.R. Shinefield, and S. Ling Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia Pediatr Infect Dis J 21 2002 810 815
32. J.C. Butler, R.F. Breiman, H.B. Lipman, J. Hofmann, and R.R. Facklam Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine J Infect Dis 171 1995 885 889
33. J. Eskola, T. Kilpi, and A. Palmu Efficacy of a pneumococcal conjugate vaccine against acute otitis media N Engl J Med 344 2001 403 409
34. B. Fireman, S.B. Black, H.R. Shinefield, J. Lee, E. Lewis, and P. Ray Impact of the pneumococcal conjugate vaccine on otitis media Pediatr Infect Dis J 22 2003 10 16
35. R. Veenhoven, D. Bogaert, and C. Uiterwaal Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study Lancet 361 2003 2189 2195
36. D.W. Teele, J.O. Klein, and B. Rosner Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study J Infect Dis 160 1989 83 94
37. S. Berman Otitis media in children N Engl J Med 332 1995 1560 1565
38. L.F. McCaig, R.E. Besser, and J.M. Hughes Trends in antimicrobial prescribing rates for children and adolescents JAMA 287 2002 3096 3102
39. F. Zhou, K.M. Bisgard, H.R. Yusuf, R.R. Deuson, S.K. Bath, and T.V. Murphy Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis Pediatrics 110 2002 653 661
40. T.A. Lieu, G.T. Ray, and S.B. Black Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children JAMA 283 2000 1460 1468
41. CDC. Estimated vaccination coverage with 3 + doses of pneumococcal conjugate vaccine among children 19-35 months of age by race/ethnicity and by state and immunization action plan area. US National Immunization Survey Q1/2002-Q4/2002. Available at: http://www.cdc.gov/nip/coverage/NIS/02/ tab29a_3pcv_race_iap.xls. Accessed April 11, 2005.
42. C.G. Whitney, M.M. Farley, and J. Hadler Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States N Engl J Med 343 2000 1917 1924
43. R. Dagan, and D. Fraser Conjugate pneumococcal vaccine and antibiotic-resistant Streptococcus pneumoniae: herd immunity and reduction of otitis morbidity Pediatr Infect Dis J 19 2000 S79 S87
44. J.R. Casey, and M.E. Pichichero Changes in frequency and pathogens causing acute otitis media in 1995-2003 Pediatr Infect Dis J 23 2004 824 828
45. B. Beall, M.C. McEllistrem, and R.E. Gertz Jr. Emergence of a novel penicillin-nonsusceptible, invasive serotype 35B clone of Streptococcus pneumoniae within the United States J Infect Dis 186 2002 118 122
46. N. Porat, G. Barkai, M.R. Jacobs, R. Trefler, and R. Dagan Four antibiotic-resistant Streptococcus pneumoniae clones unrelated to the pneumococcal conjugate vaccine serotypes, including 2 new serotypes, causing acute otitis media in southern Israel J Infect Dis 189 2004 385 392
47. M.R. Reichler, A.A. Allphin, and R.F. Breiman The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio J Infect Dis 166 1992 1346 1353
48. R. Dagan, R. Melamed, M. Muallem, L. Piglansky, and P. Yagupsky Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines J Infect Dis 174 1996 1352 1355
49. J.M. Gwaltney Jr., M.A. Sande, R. Austrian, and J.O. Hendley Spread of Streptococcus pneumoniae in families: II. relation of transfer of S. pneumoniae to incidence of colds and serum antibody J Infect Dis 132 1975 62 68
50. J. Shimada, N. Yamanaka, and M. Hotomi Household transmission of Streptococcus pneumoniae among siblings with acute otitis media J Clin Microbiol 40 2002 1851 1853
51. N. Givon-Lavi, D. Fraser, N. Porat, and R. Dagan Spread of Streptococcus pneumoniae and antibiotic-resistant S. pneumoniae from day-care center attendees to their younger siblings J Infect Dis 186 2002 1608 1614
52. A.K. Takala, J. Eskola, and M. Leinonen Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine J Infect Dis 164 1991 982 986
53. T.V. Murphy, P. Pastor, F. Medley, M.T. Osterholm, and D.M. Granoff Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine J Pediatr 122 1993 517 523
54. Block SL, Hedrick JA, Hartrison CJ. Widespread use of conjugated pneumococcal vaccine significantly reduces rates of AOM and antibiotic usage [Abstract 1135]. Presented at Pediatric Academic Societies. San Francisco, 2004.
55. E. Leibovitz, S. Raiz, and L. Piglansky Resistance pattern of middle ear fluid isolates in acute otitis media recently treated with antibiotics Pediatr Infect Dis J 17 1998 463 469
56. B. Lopez, M.D. Cima, and F. Vazquez Epidemiological study of Streptococcus pneumoniae carriers in healthy primary-school children Eur J Clin Microbiol Infect Dis 18 1999 771 776
57. F. del Castillo, F. Baquero-Artigao, and A. Garcia-Perea Influence of recent antibiotic therapy on antimicrobial resistance of Streptococcus pneumoniae in children with acute otitis media in Spain Pediatr Infect Dis J 17 1998 94 97
58. R. Dagan, M. Sikuler-Cohen, O. Zamir, J. Janco, N. Givon-Lavi, and D. Fraser Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees Pediatr Infect Dis J 20 2001 951 958
59. S.L. Block, J. Hedrick, and C.J. Harrison Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media Pediatr Infect Dis J 23 2004 829 833
60. G. Regev-Yochay, R. Dagan, and M. Raz Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in children JAMA 292 2004 716 720
61. M. Nesin, M. Ramirez, and A. Tomasz Capsular transformation of a multidrug-resistant Streptococcus pneumoniae in vivo J Infect Dis 177 1998 707 713
62. P. Nilsson, and M.H. Laurell Carriage of penicillin-resistant Streptococcus pneumoniae by children in day-care centers during an intervention program in Malmo, Sweden Pediatr Infect Dis J 20 2001 1144 1149
63. D.M. Barnes, S. Whittier, P.H. Gilligan, S. Soares, A. Tomasz, and F.W. Henderson Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: evidence suggesting capsular transformation of the resistant strain in vivo J Infect Dis 171 1995 890 896
64. G. Gherardi, C.G. Whitney, R.R. Facklam, and B. Beall Major related sets of antibiotic-resistant pneumococci in the United States as determined by pulsed-field gel electrophoresis and pbp1a-pbp2b-pbp2x-dhf restriction profiles J Infect Dis 181 2000 216 229
65. T.J. Coffey, M.C. Enright, and M. Daniels Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae Mol Microbiol 27 1998 73 83
66. T.J. Coffey, C.G. Dowson, and M. Daniels Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae Mol Microbiol 5 1991 2255 2260
67. T. Kelly, J.P. Dillard, and J. Yother Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae Infect Immun 62 1994 1813 1819
68. M.C. McEllistrem, J. Adams, E.O. Mason, and E.R. Wald Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine J Infect Dis 188 2003 1679 1684
69. J.O. Klein Management of the febrile child without a focus of infection in the era of universal pneumococcal immunization Pediatr Infect Dis J 21 2002 584 588
70. N. Kuppermann The evaluation of young febrile children for occult bacteremia: time to reevaluate our approach? Arch Pediatr Adolesc Med 156 2002 855 857
71. D.M. Jaffe, R.R. Tanz, A.T. Davis, F. Henretig, and G. Fleisher Antibiotic administration to treat possible occult bacteremia in febrile children N Engl J Med 317 1987 1175 1180
72. J.E. McGowan Jr., L. Bratton, J.O. Klein, and M. Finland Bacteremia in febrile children seen in a "walk-in" pediatric clinic N Engl J Med 288 1973 1309 1312
73. L.J. Baraff, J.W. Bass, and G.R. Fleisher Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research Ann Emerg Med 22 1993 1198 1210
74. E.R. Alpern, E.A. Alessandrini, L.M. Bell, K.N. Shaw, and K.L. McGowan Occult bacteremia from a pediatric emergency department: current prevalence, time to detection, and outcome Pediatrics 106 2000 505 511
75. G.M. Lee, and M.B. Harper Risk of bacteremia for febrile young children in the post-Haemophilus influenzae type b era Arch Pediatr Adolesc Med 152 1998 624 628
76. M.L. Stoll, and L.G. Rubin Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine: a study from a Children's Hospital Emergency Department and Urgent Care Center Arch Pediatr Adolesc Med 158 2004 671 675
77. L.G. Yamamoto Revising the decision analysis for febrile children at risk for occult bacteremia in a future era of widespread pneumococcal immunization Clin Pediatr (Phila) 40 2001 583 594
78. G.M. Lee, G.R. Fleisher, and M.B. Harper Management of febrile children in the age of the conjugate pneumococcal vaccine: a cost-effectiveness analysis Pediatrics 108 2001 835 844
79. K.C. Lee, J.A. Finkelstein, and I.L. Miroshnik Pediatricians' self-reported clinical practices and adherence to national immunization guidelines after the introduction of pneumococcal conjugate vaccine Arch Pediatr Adolesc Med 158 2004 695 701